BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Induction of insulin receptor substrate-2 expression by Fc fusion to exendin-4 overexpressed in E. coli: a potential long-acting glucagon-like peptide-1 mimetic

  • Published : 2010.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Exendin-4 (Ex-4), a peptide secreted from the salivary glands of the Gila monster lizard, can increase pancreatic $\beta$-cell growth and insulin secretion by activating glucagon-like peptide-1 receptor. In this study, we expressed a fusion protein consisting of exendin-4 and the human immunoglobulin heavy chain (Ex-4/IgG-Fc) in E. coli and explored its potential therapeutic use for the treatment of insulin-resistant type 2 diabetes. Here, we show that the Ex-4/IgG-Fc fusion protein induces expression of insulin receptor substrate-2 in rat insulinoma INS-1 cells. Our findings therefore suggest that Ex-4/IgG-Fc overexpressed in E. coli could be used as a potential, long-acting glucagon-like peptide-1 mimetic.

Keywords

References

  1. Eng, J., Kleinman, W. A., Singh, L., Singh, G. and Raufman, J. P. (1992) Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J. Biol. Chem. 267, 7402-7405
  2. Hui, H., Nourparvar, A., Zhao, X. and Perfetti, R. (2003) Glucagon-like peptide-1 inhibits apoptosis of insulin- secreting cells via a cyclic 5'-adenosine monophosphatedependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 144, 1444-1455 https://doi.org/10.1210/en.2002-220897
  3. Xu, G., Stoffers, D. A., Habener, J. F. and Bonner-Weir, S. (1999) Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48, 2270-2276 https://doi.org/10.2337/diabetes.48.12.2270
  4. Deacon, C. F., Johnsen, A. H. and Holst, J. J. (1995) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 80, 952-957 https://doi.org/10.1210/jc.80.3.952
  5. Giannoukakis, N. (2003) Exenatide. Amylin/Eli Lilly. Curr. Opin. Investig. Drugs. 4, 459-465
  6. Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E. and Maggs, D. G. (2008) Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr. Med. Res. Opin. 24, 275-286 https://doi.org/10.1185/030079908X253870
  7. Schmidt, S. R. (2009) Fusion-proteins as biopharmaceuticals - applications and challenges. Curr. Opin. Drug. Discov. Devel. 12, 284-295
  8. Kumar, M., Hunag, Y., Glinka, Y., Prud'homme, G. J. and Wang, Q. (2007) Gene therapy of diabetes using a novel GLP-1/IgG1-Fc fusion construct normalizes glucose levels in db/db mice. Gene Ther. 14, 162-172
  9. Kim, D. M., Chu, S. H., Kim, S., Park, Y. W. and Kim, S. S. (2009) Fc fusion to glucagon-like peptide-1 inhibits degradation by human DPP-IV, increasing its half-life in serum and inducing a potent activity for human GLP-1 receptor activation. BMB Rep. 42, 212-216 https://doi.org/10.5483/BMBRep.2009.42.4.212
  10. Soltani, N., Kumar, M., Glinka, Y., Prud'homme, G. J. and Wang, Q. (2007) In vivo expression of GLP-1/IgG-Fc fusion protein enhances beta-cell mass and protects against streptozotocin-induced diabetes. Gene Ther. 14, 981-988 https://doi.org/10.1038/sj.gt.3302944
  11. Huang, Y. S., Chen, Z., Chen, Y. Q., Ma, G. C., Shan, J. F., Liu, W. and Zhou, L. F. (2008) Preparation and characterization of a novel exendin-4 human serum albumin fusion protein expressed in Pichia pastoris. J. Pept. Sci. 14, 588-595 https://doi.org/10.1002/psc.942
  12. Park, S., Dong, X., Fisher, T. L., Dunn, S., Omer, A. K., Weir, G. and White, M. F. (2006) Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. J. Biol. Chem. 281, 1159-1168 https://doi.org/10.1074/jbc.M508307200
  13. Jhala, U. S., Canettieri, G., Screaton, R. A., Kulkarni, R. N., Krajewski, S., Reed, J., Walker, J., Lin, X., White, M. and Montminy, M. (2003) cAMP promotes pancreatic b-cell survival via CREB-mediated induction of IRS2. Genes Dev. 17, 1575-1580 https://doi.org/10.1101/gad.1097103
  14. White, M. F. (2003) Insulin signaling in health and disease. Science 302, 1710-1711 https://doi.org/10.1126/science.1092952
  15. Parkes, D., Jodka, C., Smith, P., Nayak, S., Rinehart, L., Gingerich, R., Chen, K. and Young, A., (2001) Pharmacokinetic actions of exendin-4 in the rat: Comparison with glucagon-like peptide-1. Drug. Dev. Res. 54, 260-267
  16. Leahy, D. J., Dann, C. E., 3rd, Longo, P., Perman, B. and Ramyar, K. X. (2000) A mammalian expression vector for expression and purification of secreted proteins for structural studies. Protein Expr. Purif. 20, 500-506 https://doi.org/10.1006/prep.2000.1331

Cited by

  1. Double-strand adeno-associated virus-mediated exendin-4 expression in salivary glands is efficient in a diabetic rat model vol.103, pp.3, 2014, https://doi.org/10.1016/j.diabres.2013.12.006